Drug Trial Radar · NCT01132690
A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Last checked: Nov 20, 2026Latest source record: Oct 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Aug 2010
Primary completion
May 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 28, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, double-blind trial to assess the safety and efficacy of taliglucerase alfa in untreated subjects (2 to \<18 years old) with Gaucher disease randomly assigned to treatment with one of two doses, 30 or 60 units/kg. Subjects will receive an intravenous (IV) infusion of taliglucerase alfa every two weeks. The total duration of treatment will be 12 months. At the end of the 12-month treatment period eligible subjects will be offered enrollment in an open-label extension study if taliglucerase alfa is not commercially available.
Conditions
- Gaucher Disease
Interventions
Taliglucerase alfaDrug
Taliglucerase alfa for infusion every two weeks for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- HemoglobinTime frame: Every 3 months for 12 months
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Shaare Zedek Medical Center
Jerusalem, Israel
Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C)
Barrio Sajonia Asunción, Paraguay
Morningside Medi-Clinic
Morningside, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.